ABIVAX
Clinical-stage biotech developing therapeutics for chronic inflammatory diseases.
ABVX | PA
Overview
Corporate Details
- ISIN(s):
- FR0012333284 (+1 more)
- LEI:
- 969500D8TMNB184OJU95
- Country:
- France
- Address:
- 7 BOULEVARD HAUSSMANN, 75009 PARIS
- Website:
- https://www.abivax.com
- Sector:
- Manufacturing
Description
Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-03-26 22:05 |
Abivax publie ses rapports financiers auprès des autorités françaises et améric…
|
French | 78.3 KB | ||
| 2025-03-26 22:05 |
Abivax publie ses rapports financiers aupres des autorites francaises et americ…
|
French | 9.2 KB | ||
| 2025-03-24 21:56 |
ABIVAX URD 2025
|
French | 6.3 MB | ||
| 2025-03-24 08:30 |
Abivax Annonce ses Résultats Financiers pour l’Exercice 2024
|
French | 280.8 KB | ||
| 2025-03-24 08:30 |
Abivax Announces Full Year 2024 Financial Results
|
English | 23.5 KB | ||
| 2025-03-14 15:16 |
Franchissement de seuil
|
French | 286.4 KB | ||
| 2025-03-13 12:38 |
Franchissement de seuil
|
French | 285.8 KB | ||
| 2025-02-26 18:00 |
ABIVAX: Nombre dactions composant le capital social et nombre total de droits d…
|
French | 20.8 KB | ||
| 2025-02-25 18:00 |
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits …
|
French | 96.7 KB | ||
| 2025-02-25 18:00 |
ABIVAX: Nombre dactions composant le capital social et nombre total de droits d…
|
French | 20.8 KB | ||
| 2025-02-22 08:30 |
Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025
|
English | 5.3 KB | ||
| 2025-02-21 08:30 |
Abivax organisera un webcast animé par un leader d’opinion de renom le 17 mars …
|
French | 3.8 MB | ||
| 2025-02-21 08:30 |
Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025
|
English | 5.3 KB | ||
| 2025-02-18 10:03 |
Franchissement de seuil et déclaration d'intention
|
French | 388.0 KB | ||
| 2025-01-29 08:30 |
Abivax Publishes 2025 Financial Calendar
|
English | 8.4 KB |
Automate Your Workflow. Get a real-time feed of all ABIVAX filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ABIVAX
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ABIVAX via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-11 | N/A | Other | Buy | 319,107 | N/A |
| 2024-03-01 | N/A | Other | Buy | 7,000 | 91,557.90 EUR |
| 2023-12-19 | N/A | Other | Sell | 50,000 | 482,500.00 EUR |
| 2023-12-11 | N/A | Other | Sell | 2,062 | 19,382.80 EUR |
| 2023-11-13 | N/A | Other | Buy | 4 | 39.84 EUR |
| 2023-07-13 | N/A | Other | Sell | 192,781 | 3,101,480.01 EUR |
| 2023-03-27 | N/A | Other | Other | 38,461 | 249,996.50 EUR |
| 2023-02-27 | N/A | Other | Other | 1,535,000 | 9,977,500.00 EUR |
Peer Companies
